来那度胺联合利妥昔单抗作为套细胞淋巴瘤初始治疗的九年随访
这项多中心2期研究报告了来那度胺联合利妥昔单抗作为套细胞淋巴瘤初始治疗9年随访结果:中位随访103个月时,36例可评估患者中17例(47%)仍处于缓解,9年无进展生存率和总生存率分别为51%和66%,长期随访显示持续持久缓解且安全性可控。
要点
- 中位随访103个月时,36例可评估患者中17例(47%)仍处于缓解。
- 9年无进展生存率和总生存率分别为51%和66%。
- 维持治疗期间周围神经病变发生率高于诱导治疗(29% vs 8%),21%患者发生第二肿瘤,其中5%为侵袭性恶性肿瘤。
核心结论
- 长期随访显示,来那度胺联合利妥昔单抗作为套细胞淋巴瘤初始诱导治疗继续表现出持久缓解,且安全性可控。
研究设计与样本
- 多中心2期研究,评估来那度胺联合利妥昔单抗作为套细胞淋巴瘤初始治疗,双药方案用作诱导和维持直至进展,3年后可选停药,36例可评估患者,中位随访103个月,试验注册号NCT01472562。
主要发现
- 既往报告可评估患者总缓解率为92%,其中64%达到完全缓解。
- 中位随访103个月时,36例可评估患者中17例(47%)仍处于缓解。
- 9年无进展生存率和总生存率分别为51%和66%。
- 维持治疗期间血液学不良事件包括无症状3或4级血细胞减少(中性粒细胞减少42%、血小板减少5%、贫血3%)。
- 维持治疗期间感染多为1至2级并在门诊处理(上呼吸道感染50%、尿路感染21%、鼻窦炎16%、蜂窝织炎16%、肺炎13%,其中5%需住院)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although chemoimmunotherapy is the current standard of care for initial treatment of mantle cell lymphoma (MCL), newer data suggest that there may be a role for a chemotherapy-free approach. We report the 9-year follow-up results of a multicenter, phase 2 study of lenalidomide plus rituximab (LR) as the initial treatment of MCL. The LR doublet is used as induction and maintenance until progression, with optional discontinuation after 3 years. We previously reported an overall response rate of 92% in evaluable patients, with 64% achieving a complete response. At a median follow-up of 103 months, 17 of 36 evaluable patients (47%) remain in remission. The 9-year progression-free survival and overall survival were 51% and 66%, respectively. During maintenance, hematologic adverse events included asymptomatic grade 3 or 4 cytopenia (42% neutropenia, 5% thrombocytopenia, and 3% anemia) and mostly grade 1 to 2 infections managed in the outpatient setting (50% upper respiratory infections, 21% urinary tract infections, 16% sinusitis, 16% cellulitis, and 13% pneumonia, with 5% requiring hospitalization). More patients developed grade 1 and 2 neuropathy during maintenance therapy (29%) than during induction therapy (8%). Twenty-one percent of patients developed secondary malignancies, including 5% with invasive malignancies, whereas the remainder were noninvasive skin cancers treated with local skin-directed therapy. Two patients permanently discontinued therapy because of concerns of immunosuppression during the COVID-19 pandemic. With long-term follow-up, LR continues to demonstrate prolonged, durable responses with manageable safety as initial induction therapy. This trial was registered at www.clinicaltrials.gov as #NCT01472562.
引用
- Yamshon S, Chen GZ, Gribbin C, et al. Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood Adv. 2023. PMID: 37682791. doi:10.1182/bloodadvances.2023010606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。